During restoration of damaged teeth in dental clinics, dentin bonding agents are usually overlaid with restorative resin composites. The purpose of this study was to investigate the effects of restorative resin composites on cytotoxicity of dentin bonding agents. Dentin bonding agents were placed on glass discs, pre-cured and uncured resin composite discs. Bonding agents on the glass discs and composite resins discs were light cured and used for agar overlay cytotoxicity testing. Dentin bonding agents on composite resin discs exhibited far less cytotoxicity than that on glass discs. The polymerization of resin composite increased the surface hardness and decreased the cytotoxicity of bonding agents. In conclusion, composite resins in dental restorations are expected to enhance the polymerization of dentin bonding agents and reduce the elution of resin monomers, resulting in the decrease of cytotoxicity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4012/dmj.2012-335 | DOI Listing |
J Sci Food Agric
January 2025
Laboratorio de Investigación, Desarrollo y Evaluación de Alimentos (LIDEA), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario (UNR), Santa Fe, Argentina.
Background: The antioxidant capacity of anthocyanins (AC) rapidly degrades during storage, highlighting the need for their stabilization. The conformational properties and high proline content of sodium caseinate (NaCAS), combined with the formation of NaCAS microgels in the presence of tara gum (TG) and acid gelation, suggest its potential as an effective stabilizing or encapsulating agent of AC.
Results: Spectrofluorimetric results suggest the formation of a complex between NaCAS and AC.
Curr Drug Discov Technol
January 2025
Institute of Pharmacy, AMITY University, Jaipur, Rajasthan.
Background: Our research highlights the synthesis of newer antimalarial compounds using molecular modeling studies.
Objective: The study investigates a series of isocryptolepine derivatives from previous literature, focusing on their biological activities as antimalarial agents.
Methods: Computational methods such as molecular docking and QSAR were employed to gain insights into the interaction between the synthesized compounds and the target enzyme PfDHFR-TS.
Int J Biol Macromol
January 2025
Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430070, China. Electronic address:
The healing of bacteria-infected wounds has long posed a significant clinical challenge. Traditional hydrogel wound dressings often lack self-healing properties and effective antibacterial characteristics, making wound healing difficult. In this study, a bioactive small molecule cross-linking agent 4-FPBA/Lys/4-FPBA (FLF) composed of 4-formylphenylboronic acid (4-FPBA) and lysine (Lys) was utilized to cross-link guar gum (GG) and a tannic acid/iron (TA/Fe) chelate through multiple dynamic bonds, leading to the formation of a novel self-healing hydrogel dressing GG-FLF/TA/Fe.
View Article and Find Full Text PDFJ Phys Chem Lett
January 2025
State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, China.
The Ni-N(His) coordination bond, formed between the nickel ion and histidine residues, is essential for recombinant protein purification, especially in Ni-NTA-based systems for selectively binding polyhistidine-tagged (Histag) proteins. While previous studies have explored its bond strength in a synthetic Ni-NTA-Histag system, the influence of the surrounding protein structure remains less understood. In this study, we used atomic force microscopy-based single-molecule force spectroscopy (AFM-SMFS) to quantify the Ni-N(His) bond strength in calprotectin, a biologically relevant protein system.
View Article and Find Full Text PDFRSC Med Chem
January 2025
Department of Chemistry, The State University of New York at Buffalo Natural Sciences Complex Buffalo NY 14260 USA
Small molecules targeting activating mutations within the epidermal growth factor receptor (EGFR) are efficacious anticancer agents, particularly in non-small cell lung cancer (NSCLC). Among these, lazertinib, a third-generation tyrosine kinase inhibitor (TKI), has recently gained FDA approval for use in combination with amivantamab, a dual EGFR/MET-targeting monoclonal antibody. This review delves into the discovery and development of lazertinib underscoring the improvements in medicinal chemistry properties, especially in comparison with osimertinib.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!